The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
"Court is a lottery these days." Not if you employ a decent legal firm to write your blimmin' patents. Or, at the very least, look for someone like Burford or Litigation Capital Management Limited to underwrite any legal challenge - that's IF you've got a decent case in the first place. You also have the safety net of there being a bit of a clue in there if they decline. No win, no fee?
I absolutely know I shouldn't but ;-)) ........
Might it be helpful if Ophidian could come up with a projected timetable of the future plan? I mean, it calmed the board to such an extent during those soothing early days of the LFT 🫣. (OKAY, I'M SORRY! My filter's back on 😁)
For what it's worth, as a fan of AVCT but not an investee at present, I was moderately pleased by today's RNS. I was disappointed that they had to focus on one patient in particular as that suggests less impressive results in others and a need to detract from them. The standout word "encouraging" (as in "AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity") also hasn't done the SP any favours. You can thank the rampers for undermining management of expectations over recent days on that front. Some on here will undoubtedly jump into 'overly defensive' mode at my opinion but I've just tried to be honest and, equally importantly, realistic. That said, things are still on track and the SP will almost certainly recover.
"I am reasonably confident MKS will continue to do well as the economic climate improves." JJ
Couldn't agree more and I'd go so far as to say they'll continue to do so in the face of the current climate. The UK is in a right mess but MKS and it's management continue to be a shining light in the face of this adversity, a reminder of what we once were and can hopefully rise to again. Great customer care, transitioning when needed to and top quality goods that are well presented. What's not to like?
Not ramping, just have a lot of faith in this company which has much further to go, imo.
In a Bucks store yesterday and it was extremely busy. Maybe unsurprising at this time of year but moreso than I had expected on a very cold day.
After the recent news and with the dust starting to settle, I thought this might be quite useful for those seeking to understand the science / recent announcement re. CAR-T treatment.
https://www.science.org/content/article/explainer-what-s-behind-fda-s-concern-cancer-fighting-cell-therapy-can-also-cause
After the recent news and with the dust starting to settle, I thought this might be quite useful for those seeking to understand the science / recent announcement re. CAR-T treatment.
https://www.science.org/content/article/explainer-what-s-behind-fda-s-concern-cancer-fighting-cell-therapy-can-also-cause
Thought you might be interested in this, from Dazpink on HEMO.
AbbVie signs $10 bln deal to buy cancer drugmaker ImmunoGen
https://www.reuters.com/markets/deals/abbvie-buy-immunogen-101-billion-boost-cancer-drug-portfolio-2023-11-30/
Firstly, Hemotruth, can you stop being so obviously negative, spreading your highly transparent seeds of doubt? Although, looking at your history, I guess at least you're consistent. That aside..........
Just looking back at the FDA letter details in the RNS on 10 July, one aspect that pleased me was, "The CH letter also contains several suggestions on how to improve the safety of HEMO-CAR-T. These suggestions do not and would not contribute to the CH and can be dealt with readily."
That not only says the FDA is keen to work with us but also provides them with a sense of ownership in the product through seeing their ideas being adopted by us. That can only improve the chances of them being inclined towards wanting us to succeed in our application.
".....everything I have learned in the past few years has left me disgusted with just how underhand the markets are." Whilst I agree with much of what you say and no offence intended, JustHereForHemo, there are very obvious answers to your post, one of which is, you clearly haven't learnt (any more than the rest of us) or you wouldn't still be here. I agree though,flippin' frustrating and we are too frequently left wondering why the regulators aren't getting their heads out of their ar**s.
I realise that, Pumpky, but the science, relatively small SP movement (on both sides of the pond) and some decent buying volume suggest there is no great concern amongst those far better qualified than us to 'know'.
As somebody whose timing has been blimmin' awful as far as this share's concerned, I'd still defend Stu'. I want to see ALL news that could potentially affect companies I'm invested in. That is surely preferable to sitting here in blind ignorance and the story he posted was covered by just about every major US news org. Unless those criticising him were raised in North Korea, I cannot see why there's a need to condemn him for posting a factual story of relevance.